Mersana Therapeutics (MRSN) Competitors $2.22 0.00 (0.00%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends MRSN vs. ARCT, STOK, AVDL, ZYME, SEPN, COGT, BCAX, BCYC, COLL, and PAHCShould you be buying Mersana Therapeutics stock or one of its competitors? The main competitors of Mersana Therapeutics include Arcturus Therapeutics (ARCT), Stoke Therapeutics (STOK), Avadel Pharmaceuticals (AVDL), Zymeworks (ZYME), Septerna (SEPN), Cogent Biosciences (COGT), Bicara Therapeutics (BCAX), Bicycle Therapeutics (BCYC), Collegium Pharmaceutical (COLL), and Phibro Animal Health (PAHC). These companies are all part of the "pharmaceutical products" industry. Mersana Therapeutics vs. Arcturus Therapeutics Stoke Therapeutics Avadel Pharmaceuticals Zymeworks Septerna Cogent Biosciences Bicara Therapeutics Bicycle Therapeutics Collegium Pharmaceutical Phibro Animal Health Arcturus Therapeutics (NASDAQ:ARCT) and Mersana Therapeutics (NASDAQ:MRSN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability, community ranking and analyst recommendations. Do analysts prefer ARCT or MRSN? Arcturus Therapeutics presently has a consensus target price of $71.40, suggesting a potential upside of 341.56%. Mersana Therapeutics has a consensus target price of $6.00, suggesting a potential upside of 170.27%. Given Arcturus Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Arcturus Therapeutics is more favorable than Mersana Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arcturus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Mersana Therapeutics 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.88 Which has stronger valuation and earnings, ARCT or MRSN? Arcturus Therapeutics has higher revenue and earnings than Mersana Therapeutics. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than Mersana Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArcturus Therapeutics$142.47M3.07-$29.73M-$2.22-7.28Mersana Therapeutics$36.85M7.44-$171.67M-$0.61-3.64 Does the MarketBeat Community believe in ARCT or MRSN? Arcturus Therapeutics received 187 more outperform votes than Mersana Therapeutics when rated by MarketBeat users. However, 65.87% of users gave Mersana Therapeutics an outperform vote while only 65.86% of users gave Arcturus Therapeutics an outperform vote. CompanyUnderperformOutperformArcturus TherapeuticsOutperform Votes43665.86% Underperform Votes22634.14% Mersana TherapeuticsOutperform Votes24965.87% Underperform Votes12934.13% Does the media favor ARCT or MRSN? In the previous week, Mersana Therapeutics had 15 more articles in the media than Arcturus Therapeutics. MarketBeat recorded 18 mentions for Mersana Therapeutics and 3 mentions for Arcturus Therapeutics. Mersana Therapeutics' average media sentiment score of 0.56 beat Arcturus Therapeutics' score of 0.51 indicating that Mersana Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcturus Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mersana Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals hold more shares of ARCT or MRSN? 94.5% of Arcturus Therapeutics shares are held by institutional investors. Comparatively, 93.9% of Mersana Therapeutics shares are held by institutional investors. 15.3% of Arcturus Therapeutics shares are held by insiders. Comparatively, 11.8% of Mersana Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Is ARCT or MRSN more profitable? Arcturus Therapeutics has a net margin of -36.39% compared to Mersana Therapeutics' net margin of -214.20%. Arcturus Therapeutics' return on equity of -22.39% beat Mersana Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Arcturus Therapeutics-36.39% -22.39% -14.81% Mersana Therapeutics -214.20%-401.37%-38.61% Which has more risk and volatility, ARCT or MRSN? Arcturus Therapeutics has a beta of 2.64, meaning that its stock price is 164% more volatile than the S&P 500. Comparatively, Mersana Therapeutics has a beta of 1.5, meaning that its stock price is 50% more volatile than the S&P 500. SummaryArcturus Therapeutics beats Mersana Therapeutics on 12 of the 18 factors compared between the two stocks. Ad Weiss RatingsTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.This could be his favorite coin. Get Mersana Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MRSN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MRSN vs. The Competition Export to ExcelMetricMersana TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$274.24M$6.48B$5.05B$8.87BDividend YieldN/A8.12%4.97%4.06%P/E Ratio-3.645.5697.3414.18Price / Sales7.44348.141,218.4289.42Price / CashN/A22.1533.5132.79Price / Book222.007.885.805.12Net Income-$171.67M$153.61M$119.07M$225.99M7 Day Performance-11.90%-2.00%-1.83%-1.32%1 Month Performance5.71%-7.47%-3.64%0.60%1 Year Performance40.51%31.80%31.62%26.23% Mersana Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MRSNMersana Therapeutics4.3673 of 5 stars$2.22flat$6.00+170.3%+38.8%$274.24M$36.85M-3.64150Analyst RevisionARCTArcturus Therapeutics2.0511 of 5 stars$16.17-10.5%$71.40+341.6%-33.7%$489.19M$142.47M-7.28180STOKStoke Therapeutics3.8396 of 5 stars$11.31-2.6%$20.83+84.2%+171.2%$614.95M$8.78M0.00100AVDLAvadel Pharmaceuticals2.3424 of 5 stars$10.75+0.3%$24.43+127.2%-7.5%$1.03B$27.96M0.00154Short Interest ↓ZYMEZymeworks2.4008 of 5 stars$14.55-1.5%$19.00+30.6%+74.0%$1.02B$76.01M0.00290SEPNSepternaN/A$22.50-7.0%$43.67+94.1%N/A$1.02BN/A0.00N/AAnalyst ForecastNews CoverageGap UpCOGTCogent Biosciences2.866 of 5 stars$9.08+0.2%$14.83+63.4%+20.6%$1.00BN/A0.0080Analyst RevisionBCAXBicara Therapeutics3.1692 of 5 stars$18.38-4.9%$43.33+135.8%N/A$1.00BN/A0.0032Analyst RevisionBCYCBicycle Therapeutics2.8475 of 5 stars$20.36-0.6%$40.13+97.1%+49.4%$968.12M$26.98M-6.19240Analyst RevisionCOLLCollegium Pharmaceutical3.9744 of 5 stars$30.00+0.8%$42.60+42.0%+17.2%$967.50M$566.77M12.93210PAHCPhibro Animal Health4.2227 of 5 stars$23.39-1.5%$16.50-29.5%+123.4%$961.95M$1.02B54.401,940Analyst Downgrade Related Companies and Tools Related Companies ARCT Competitors STOK Competitors AVDL Competitors ZYME Competitors SEPN Competitors COGT Competitors BCAX Competitors BCYC Competitors COLL Competitors PAHC Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MRSN) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mersana Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mersana Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
